Stroke Preclinical Assessment Network
What is SPAN? The Stroke Pre-Clinical Assessment Network (SPAN) seeks to conduct late-stage preclinical studies of putative neuroprotectants combined with reperfusion. SPAN utilizes a novel, adaptive, secured system for parallel testing of promising interventions designed to extend the treatment time window and/or improve outcome compared to reperfusion when combined with thrombolysis, thrombectomy or both.
Why SPAN? SPAN was established to address a significant need in the scientific investigation of stroke treatment. In the past, a plethora of putative neuroprotectants proceeded to clinical trial based on favorable preclinical assessment, only to fail in subsequent clinical trials of human stroke patients. The recent successful development of thrombectomy for acute ischemic stroke generated considerable enthusiasm for re-testing treatment candidates in combination with thrombectomy. Thus, SPAN is intended to screen and select highly promising treatment candidates for possible further study in human clinical trials.
Announcement SPAN 2.0 Funding Opportunity!
The purpose of this funding opportunity announcement (FOA) is to invite applications for testing laboratories, research projects, and Phase II SBIR applications to test promising cerebrovascular interventions in the NINDS Stroke Preclinical Assessment Network (SPAN).
SPAN Invited to give a Symposium at ISC 2022
Presenters: Patrick D. Lyden, Anjali Chauhan, Cenk Ayata, Lauren H, Sansing
Moderators: Francesca Bosetti and Eduardo Candelario-jalil
Session Type: Invited Symposium
Session Date: Wednesday, February 9, 2022, 5:00pm-6:00pm (local)
Location: New Orleans, LA
USC Named The SPAN Coordinating Center
Dubbed the Stroke Preclinical Assessment Network (SPAN), the NIH-funded program, under the leadership of Patrick Lyden, MD, professor of Physiology and Neuroscience at the Zilkha Neurogenetic Institute of the Keck School of Medicine at USC, will assess the effectiveness of six potential therapies for stroke.
